{
    "type": "ETP",
    "ucits": false,
    "leverage": true,
    "derivatives": true,
    "swaps": false,
    "inverse": true,
    "replication_method": "synthetic",
    "complex_factors": [
        "Leverage",
        "Inverse exposure",
        "Synthetic replication",
        "Daily rebalancing compounding effect",
        "Derivative use integral to strategy",
        "Counterparty and collateral risk",
        "High risk rating (7/7)",
        "Short recommended holding period",
        "Potential illiquidity and early redemption risk"
    ],
    "classification": "complex",
    "supporting_data": "The product is a collateralised exchange traded security (ETP) aiming to deliver -3 times the daily performance of the Solactive Magnificent 7 Index, indicating significant leverage and inverse exposure. It uses synthetic replication involving derivatives integral to the investment strategy, which introduces counterparty and collateral risks that are difficult for retail investors to understand. The product has a very high risk rating (7/7), a recommended holding period of only 1 day due to the compounding effect of daily leverage rebalancing, and no capital protection. The structure and risks are complex, requiring sophisticated investor knowledge. The product is not UCITS compliant and is explicitly described as 'not simple and may be difficult to understand' in its KID. These factors align with MiFID II Article 57 and ESMA guidelines that classify such leveraged, synthetic, inverse ETPs as complex financial instruments requiring appropriateness assessments."
}